Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences
ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger
ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences
Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger Agreement
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SILK, ALIM, INFN on Behalf of Shareholders
ALIMERA SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alimera Sciences, Inc. - ALIM
Alimera Sciences Reports Second Quarter 2024 Results
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, DOMA, ALE on Behalf of Shareholders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.